- Home
- SCD vs LXRX Comparison
SCD vs LXRX Comparison
Compare SCD & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCD
- LXRX
- Stock Information
- Founded
- SCD 2003
- LXRX 1995
- Country
- SCD United States
- LXRX United States
- Employees
- SCD N/A
- LXRX N/A
- Industry
- SCD Trusts Except Educational Religious and Charitable
- LXRX Biotechnology: Pharmaceutical Preparations
- Sector
- SCD Finance
- LXRX Health Care
- Exchange
- SCD Nasdaq
- LXRX Nasdaq
- Market Cap
- SCD 248.0M
- LXRX 228.8M
- IPO Year
- SCD N/A
- LXRX 2000
- Fundamental
- Price
- SCD $16.12
- LXRX $0.63
- Analyst Decision
- SCD
- LXRX Buy
- Analyst Count
- SCD 0
- LXRX 4
- Target Price
- SCD N/A
- LXRX $3.67
- AVG Volume (30 Days)
- SCD 62.6K
- LXRX 4.1M
- Earning Date
- SCD 01-01-0001
- LXRX 05-13-2025
- Dividend Yield
- SCD 9.63%
- LXRX N/A
- EPS Growth
- SCD N/A
- LXRX N/A
- EPS
- SCD N/A
- LXRX N/A
- Revenue
- SCD N/A
- LXRX $31,213,000.00
- Revenue This Year
- SCD N/A
- LXRX N/A
- Revenue Next Year
- SCD N/A
- LXRX $46.60
- P/E Ratio
- SCD N/A
- LXRX N/A
- Revenue Growth
- SCD N/A
- LXRX 1251.21
- 52 Week Low
- SCD $11.33
- LXRX $0.28
- 52 Week High
- SCD $15.87
- LXRX $2.45
- Technical
- Relative Strength Index (RSI)
- SCD 63.98
- LXRX 50.34
- Support Level
- SCD $15.49
- LXRX $0.52
- Resistance Level
- SCD $15.99
- LXRX $0.72
- Average True Range (ATR)
- SCD 0.28
- LXRX 0.05
- MACD
- SCD 0.03
- LXRX 0.00
- Stochastic Oscillator
- SCD 92.86
- LXRX 55.52
About SCD LMP Capital and Income Fund Inc.
Lmp Capital & Income Fund Inc is a United States-based non-diversified, closed-end management investment company. Its investment objective is total return with an emphasis on income. The fund invests in a broad range of equity and fixed-income securities of both the U.S. and foreign issuers. Its long-term investments consists of investments in common stocks, convertible preferred stocks, investments in underlying funds and master limited partnerships. Maximum investment in Sales in the IT sector, Cheniere Energy in the energy sector, Ares Management and U.S. Bancorp in the financials sector and Lennar in the consumer discretionary sector, and etc.
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.